SCHEMBL2586617

SCHEMBL2586617

O=C(NCc1ccccc1)n1cc(P(=S)(c2ccccc2)c2ccccc2)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 6/20 1.00
ASAH1 Q13510 4/20 0.49
BCHE P06276 1/20 0.42
LMNA P02545 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CASP3 P42574 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
P2RX4 Q99571 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2590676 0.92 NPSR1 (1.00) NPSR1ASAH1LMNACASP3POLB
SCHEMBL2590909 0.72 NPSR1 (1.00) NPSR1ASAH1LMNAKDM4EPOLB
SCHEMBL27312078 0.68 ASAH1 (0.57) NPSR1ASAH1BCHELMNAKDM4E
SCHEMBL12175482 0.67 NPSR1 (1.00) NPSR1LMNAKDM4EPOLBSMN1; SMN2
SCHEMBL29795580 0.66 ASAH1 (1.00) NPSR1ASAH1LMNAPOLBSMN1; SMN2
SCHEMBL2589910 0.63 NPSR1 (0.59) NPSR1LMNAKDM4ECASP3POLB
SCHEMBL8527698 0.62 NPSR1 (0.45) NPSR1ASAH1BCHELMNAKDM4E
SCHEMBL8527700 0.62 MEN1 (0.46) NPSR1ASAH1BCHELMNAKDM4E
SCHEMBL5933236 0.61 ALDH1A1 (0.61) LMNAPOLBSMN1; SMN2
SCHEMBL714625 0.61 EPHX1 (0.77) LMNAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011137220-A1 SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-03 WO disclosed
WO-2011137220-A1 SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-03 WO disclosed